Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.83% | 4.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.83% | 4.78% | |||
| Cost of Revenue | 12.11% | -2.08% | |||
| Gross Profit | -8.08% | 6.77% | |||
| SG&A Expenses | 14.40% | 1.47% | |||
| Depreciation & Amortization | -2.20% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.38% | 1.10% | |||
| Operating Income | -380.98% | 43.75% | |||
| Income Before Tax | -431.06% | -603.11% | |||
| Income Tax Expenses | 128.53% | -432.17% | |||
| Earnings from Continuing Operations | -522.73% | -365.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -522.73% | -365.47% | |||
| EBIT | -380.98% | 43.75% | |||
| EBITDA | -28,856.00% | 95.74% | |||
| EPS Basic | -511.19% | -362.21% | |||
| Normalized Basic EPS | -1,778.14% | 78.45% | |||
| EPS Diluted | -511.19% | -297.50% | |||
| Normalized Diluted EPS | -1,778.14% | 78.45% | |||
| Average Basic Shares Outstanding | 1.90% | 0.89% | |||
| Average Diluted Shares Outstanding | 1.90% | 0.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||